The artificial intelligence (AI) powered Auto B-line Counter, which reportedly produces a B-line count from a six-second ultrasound clip, may facilitate more expedient and consistent assessment of abnormal lung function.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Auto B-line Counter (Butterfly Network), a handheld ultrasound tool that may help accelerate assessment of suspected lung function abnormality in patients with conditions ranging from chronic obstructive pulmonary disease (COPD) to COVID-19.
In contrast to traditional manual processes for counting B-lines from lung ultrasound scans, the Auto B-line Counter utilizes deep learning technology that can provide a B-line count from a six-second ultrasound clip, according to the Butterfly Network, the manufacturer of the modality.
Incorporating an instant percent counting technique, Butterfly Network said the algorithm for the Auto B-line Counter accounts for discrete B-lines as well as confluent B-lines by the percentage of occupied rib space.
“Our AI-enabled Auto B-line Counter empowers providers to assess lung conditions faster and with more confidence and in turn will aid in earlier detection, diagnosis, and treatment of cardiovascular diseases, a leading cause of death globally, taking nearly 18 million lives each year,” noted Jonathan Rothberg, Ph.D., the founder and interim chief executive officer of Butterfly Network.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.